Endometrial Cancer Market Size was valued at USD 15.43 Billion in 2023. The Endometrial Cancer industry is projected to grow from USD 16.89 Billion in 2024 to USD 24.08 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.21% during the forecast period (2024 - 2032). Endometrial cancer, commonly known as uterine cancer, is the abnormal development of endometrium cells in the uterus. Women with abnormal vaginal bleeding are diagnosed with endometrial cancer at an early stage. Endometrial cancer is the sixth most frequent cancer in women worldwide, according to statistics. Because of the increased frequency of endometrial cancer, the endometrial cancer market is predicted to develop significantly.
Other key factors contributing to the market's growth include rising female obesity, increased menopausal hormone therapy, changes in sedentary lifestyle, socioeconomic factors, rising consumption of unhealthy diets, rising incidence of Polycystic Ovarian Syndrome (PCOS), and rising prevalence of breast or ovarian tumors. Endometrial cancer is another factor that leads to the development of endometrial cancer. According to the American Cancer Society, diabetes women are four times more likely than non-diabetic women to get endometrial cancer. Endometrial cancer is caused by such causes in women.
In 2023, Sysmex in Japan received a partial modification approval for LYNOAMP CK19 manufacturing and marketing authorization, which broadened its gene amplification capabilities to cover endometrial and cervical cancers. Initially designed for lymph node metastasis tests in various cancers, this modification enhances diagnostic applications for additional cancer types.
In 2023, Merck’s anti-PD-1 therapy KEYTRUDA got the FDA’s nod as a single agent for advanced endometrial carcinoma with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). This approval is used in patients who have progressed after previous systemic therapy and are not suitable for curative surgery or radiation-increasing treatment options within this specific patient population subset.
In October 2022, Sysmex Corporation—based out of Japan—made public that the Japanese development and marketing authority had partially agreed to alter the gene amplifier module component of its test kit called LYNOAMP CK19. The original promotion is based on the fact that it was advertised as an examination part of gastric cancer, colorectal cancer, non-small cell lung cancer, and breast cancer, which investigates lymph node metastasis. The modification extends the range of amplified cancer genes to include endometrial and cervical cancers.
In February of 2022, Karyopharm Therapeutics Inc., a U.S.-based company, stated that initial positive results appeared from the Phase 3 evaluation of Selinexor regarding Endometrial Cancer. This investigation aimed at studying selinexor on safety and efficacy as a first-line maintenance therapy among patients suffering from advanced or recurrent endometrial cancers.
Karyopharm Therapeutics Inc., a United States-based firm, announced positive preliminary findings from the Phase III trial examining Selinexor against endometrial cancer early in the year 2022.
Around March 2021, Eisai Inc. started a program called Spot Her, intended to fight against endometrial cancer’s silence and call for the participation of women so that they can be proactive in promoting awareness about their well-being and those of other ladies, too. In collaboration with Black Health Matters, Facing Our Risk of Cancer Empowered (FORCE), and SHARE Cancer Support (SHARES), this exercise was done by Eisai Inc.
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the endometrial cancer market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.
The endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user.
The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy.
On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin.
On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.
On the basis of region, the endometrial cancer market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players in the market are
Regional Market Summary
The endometrial cancer market is dominated by North America owing to the rising prevalence of breast cancer. The US Breast Cancer Statistics projected 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in 2018. Other factors such as increasing healthcare expenditure and increasing obesity within the female population drive the market growth in this region.
It is estimated that Europe stood second in the endometrial cancer industry owing to the increasing prevalence of ovarian cancer in this region. According to the Cancer Research UK in 2015, 7270 new cases of ovarian cancer were registered in the UK. Thus, the increasing prevalence of ovarian cancer in this region influences the growth of this market in this region.
Asia-Pacific was projected to be the fastest growing region for the endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the American Diabetes Association, diabetes in South Asia is expected to rise by 150% from 2000 to 2035. This provides a favorable background for the market to grow.
The Middle East and Africa holds the least share in the endometrial cancer market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.
Johnson & Johnson (J&J) is a pharmaceutical, medical device, and consumer Product Company that conducts research develops, produces, and distributes its goods. pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; consumer products in the areas of oral care, baby care, beauty, over-the-counter (OTC) pharmaceuticals, women's health, and wound care; and medical devices for use in the fields of cardiovascular, orthopedic, general surgery, and vision care. The corporation sells its goods throughout the United States, Europe, and Asia-Pacific. J&J is based in New Brunswick, New Jersey, in the United States.
Hologic, Inc. (Hologic and the firm) is a medical technology corporation specializing in enhancing the health and well-being of women. Hologic focuses on total women's health with a spectrum of diagnostic, breast care, cosmetic treatment, gynecological, and Skeletal Health products. The Optima series of essays and molecular diagnostic tests are among the company's core diagnostic tools, which help in the overall diagnosis of human disorders. Hologic is based in Bedford, Massachusetts, in the United States.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 15.43 Billion |
| Market Size 2024 | USD 16.89 Billion |
| Market Size 2032 | USD 24.08 Billion |
| Compound Annual Growth Rate (CAGR) | 6.21% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Type of material, End user and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation. |
| Key Market Opportunities | Early Detection Technologies: Innovations in diagnostic tools present growth opportunities. Personalized Medicine: Development of targeted therapies tailored to genetic profiles |
| Key Market Dynamics | Rising Incidence Rates: Growing prevalence drives demand for treatment and diagnostics. Advancements in Treatments: New drug approvals and novel therapies enhance market potential. |
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
